Royalty Pharma plcRPRXEarnings & Financial Report
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
RPRX Q4 FY2025 Key Financial Metrics
Revenue
$622.0M
Gross Profit
N/A
Operating Profit
$388.4M
Net Profit
$214.2M
Gross Margin
N/A
Operating Margin
62.4%
Net Margin
34.4%
YoY Growth
4.8%
EPS
$0.49
Royalty Pharma plc Q4 FY2025 Financial Summary
Royalty Pharma plc reported revenue of $622.0M (up 4.8% YoY) for Q4 FY2025, with a net profit of $214.2M (up 2.9% YoY) (34.4% margin).
Key Financial Metrics
| Total Revenue | $622.0M |
|---|---|
| Net Profit | $214.2M |
| Gross Margin | N/A |
| Operating Margin | 62.4% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Royalty Pharma plc Q4 FY2025 revenue of $622.0M breaks down across 2 segments, led by Financial Royalty Assets at $592.4M (95.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Financial Royalty Assets | $592.4M | 95.2% |
| Royalty Income Other | $29.6M | 4.8% |
Royalty Pharma plc Revenue by Segment — Quarterly Trend
Royalty Pharma plc revenue by segment across the last 4 reported quarters, showing how each business line (such as Financial Royalty Assets and Royalty Income Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Financial Royalty Assets | $592.4M | $578.8M | $550.4M | $539.5M |
| Royalty Income Other | $29.6M | $30.5M | $28.2M | $28.8M |
Royalty Pharma plc Annual Revenue by Year
Royalty Pharma plc annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.4B).
Royalty Pharma plc Quarterly Revenue & Net Profit History
Royalty Pharma plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $622.0M | +4.8% | $214.2M | 34.4% |
| Q3 FY2025 | $609.3M | +7.9% | $288.2M | 47.3% |
| Q2 FY2025 | $578.7M | +7.7% | $30.2M | 5.2% |
| Q1 FY2025 | $568.2M | +0.0% | $238.3M | 41.9% |
| Q4 FY2024 | $593.6M | -0.4% | $208.2M | 35.1% |
| Q3 FY2024 | $564.7M | +5.3% | $544.0M | 96.3% |
| Q2 FY2024 | $537.3M | -0.2% | $102.0M | 19.0% |
| Q1 FY2024 | $568.0M | -17.0% | $4.8M | 0.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $568.0M | $537.3M | $564.7M | $593.6M | $568.2M | $578.7M | $609.3M | $622.0M |
| YoY Growth | -17.0% | -0.2% | 5.3% | -0.4% | 0.0% | 7.7% | 7.9% | 4.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $16.13B | $17.66B | $18.04B | $18.22B | $17.61B | $18.32B | $19.35B | $19.62B |
| Liabilities | $6.27B | $7.90B | $7.78B | $7.88B | $7.82B | $8.82B | $9.73B | $9.91B |
| Equity | $9.86B | $9.75B | $10.26B | $10.34B | $9.79B | $9.50B | $9.62B | $9.71B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $664.6M | $658.2M | $703.6M | $742.5M | $596.1M | $364.0M | $702.6M | $827.1M |